Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Severe hypertriglyceridaemia is associated with pancreatitis and chronic pancreatitis-induced diabetes. Familial chylomicronaemia syndrome (FCS) is a rare autosomal recessive disorder of lipid metabolism characterised by high levels of triglycerides (TGs) due to failure of chylomicron clearance. It causes repeated episodes of severe abdominal pain, fatigue and attacks of acute pancreatitis. There are few current options for its long-term management. The only universal long-term therapy is restriction of total dietary fat intake to <10-15% of daily calories (15 to 20g per day). Many patients have been treated with fibrates and statins with a variable response, but many remain susceptible to pancreatitis. Other genetic syndromes associated with hypertriglyceridaemia include familial partial lipodystrophy (FPLD). Targeting apolipoprotein C3 (apoC3) offers the ability to increase clearance of chylomicrons and other triglyceride-rich lipoproteins. Volanesorsen is an antisense oligonucleotide (ASO) inhibitor of apoC3, which reduces TG levels by 70-80% which has been shown also to reduce rates of pancreatitis and improve well-being in FCS and reduce TGs and improve insulin resistance in FPLD. It is now undergoing licensing and payer reviews. Further developments of antisense technology including small interfering RNA therapy to apoC3 as well as other approaches to modulating triglycerides are in development for this rare disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1715944 · Cited by 669
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701329 · Cited by 573
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404
Graham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300367 · Cited by 377
Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis
Pedersen, S. B., Langsted, A., & Nordestgaard, B. G. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.6875 · Cited by 270 · cited 1×
“The risk of pancreatitis and CVD is significantly increased in subjects with non-fasting TG concentrations >443mg/dl (5mmol/L).(5) An extreme TG group (>2000mg/ dl; ~20mmol/L) has been suggested to have a 25-fold increase risk of pancreatitis(6) though many cases seem to present at >3000mg/dl (35mmol/L).”
BackgroundMoulin, P., Dufour, R., Averna, M., Arca, M., Cefalù, A. B., Noto, D., D'Erasmo, L., Di Costanzo, A., Marçais, C., Alvarez-Sala Walther, L. A., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.814 · Cited by 247
Alexander, V. J., Xia, S., Hurh, E., Hughes, S. G., O’Dea, L., Geary, R. S., Witztum, J. L., & Tsimikas, S. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz209 · Cited by 231
Severe hypertriglyceridemia is primarily polygenic
Dron, J. S., Wang, J., Cao, H., McIntyre, A. D., Iacocca, M. A., Menard, J. R., Movsesyan, I., Malloy, M. J., Pullinger, C. R., Kane, J. P., et al. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.10.006 · Cited by 222
Lipid-Modifying Therapies and Risk of Pancreatitis: A Meta-analysis
Preiss, D., Tikkanen, M. J., Welsh, P., Ford, I., Lovato, L. C., Elam, M. B., LaRosa, J. C., DeMicco, D. A., Colhoun, H. M., Goldenberg, I., et al. (2012) · JAMA · doi:10.1001/jama.2012.8439 · Cited by 181
Digenio, A., Dunbar, R. L., Alexander, V. J., Hompesch, M., Morrow, L., Lee, R. G., Graham, M. J., Hughes, S. G., Yu, R., Singleton, W., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0126 · Cited by 170
Sacks, F. M. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000146 · Cited by 168
Clinical and biochemical features of different molecular etiologies of familial chylomicronemia
Hegele, R. A., Berberich, A. J., Ban, M. R., Wang, J., Digenio, A., Alexander, V. J., D'Erasmo, L., Arca, M., Jones, A., Bruckert, E., et al. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.03.093 · Cited by 165
Mendivil, C. O., Zheng, C., Furtado, J., Lel, J., & Sacks, F. M. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.197830 · Cited by 145
Diagnostic algorithm for familial chylomicronemia syndrome
Stroes, E., Moulin, P., Parhofer, K. G., Rebours, V., Löhr, J.-M., & Averna, M. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2016.10.002 · Cited by 130
Chait, A., & Eckel, R. H. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0203 · Cited by 128
Meyers, C. D., Tremblay, K., Amer, A., Chen, J., Jiang, L., & Gaudet, D. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0006-5 · Cited by 110
Gaudet, D., Stroes, E. S., Méthot, J., Brisson, D., Tremblay, K., Bernelot Moens, S. J., Iotti, G., Rastelletti, I., Ardigo, D., Corzo, D., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.158 · Cited by 100
Lomitapide: a review of its clinical use, efficacy, and tolerability
Alonso, R., Cuevas, A., & Mata, P. (2019) · Core Evidence · doi:10.2147/ce.s174169 · Cited by 81
Rashid, N., Sharma, P. P., Scott, R. D., Lin, K. J., & Toth, P. P. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.02.019 · Cited by 66
Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism
Minicocci, I., Tikka, A., Poggiogalle, E., Metso, J., Montali, A., Ceci, F., Labbadia, G., Fontana, M., Di Costanzo, A., Maranghi, M., et al. (2016) · Journal of Lipid Research · doi:10.1194/jlr.p066183 · Cited by 56
Arca, M., Hsieh, A., Soran, H., Rosenblit, P., O’Dea, L., & Stevenson, M. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1487290 · Cited by 49
Björnson, E., Packard, C. J., Adiels, M., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Lundbom, J., et al. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13017 · Cited by 46 · cited 1×
“While chylomicronaemia predominates, patients often have elevated plasma levels of CM remnants and some VLDL as well.(19) Lipoprotein electrophoresis demonstrates a type 1 (CM) or type 5 (excess VLDL) pattern.”
BackgroundExtreme hypertriglyceridemia: genetic diversity, pancreatitis, pregnancy, and prevalence
Chyzhyk, V., Kozmic, S., Brown, A. S., Hudgins, L. C., Starc, T. J., Davila, A. D., Blevins, T. C., Diffenderfer, M. R., He, L., Geller, A. S., et al. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.09.007 · Cited by 44 · cited 1×
“Thus, having FCS has profound effects on employment status, emotional/mental well-being, and social relationship.(14,15)”
BackgroundAhmad, Z., & Wilson, D. P. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.08.010 · Cited by 43
Wong, A. T. Y., Chan, D. C., Barrett, P. H. R., Adams, L. A., & Watts, G. F. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4037 · Cited by 30
Gouni-Berthold, I., Alexander, V., Digenio, A., DuFour, R., Steinhagen-Thiessen, E., Martin, S., Moriarty, P., Hughes, S., Jones, R., Witztum, J. L., et al. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.08.003 · Cited by 21
Roundtable on etiology of familial chylomicronemia syndrome
Brown, W. V., Gaudet, D., Goldberg, I., & Hegele, R. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.12.015 · Cited by 18
A 1-month-old infant with chylomicronemia due to GPIHBP1 gene mutation treated by plasmapheresis
Jung, M. K., Jin, J., Kim, H. O., Kwon, A., Chae, H. W., Kang, S. J., Kim, D. H., & Kim, H.-S. (2017) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2017.22.1.68 · Cited by 14
Cited by
A Modern Approach to Dyslipidemia
Berberich, A. J., & Hegele, R. A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab037 · Cited by 469
Advances in treatment of Dyslipidemia
Dybiec, J., Baran, W., Dąbek, B., Fularski, P., Młynarska, E., Radzioch, E., Rysz, J., & Franczyk, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713288 · Cited by 55
“Volanesorsen (ISIS 304801; ISIS-ApoC-III Rx) is a second generation 2′-O-methoxyethyl (2′-MOE) antisense oligonucleotide (ASO) [91,92].”
BackgroundRNA-targeting strategies as a platform for ocular gene therapy
Kumar, S., Fry, L. E., Wang, J.-H., Martin, K. R., Hewitt, A. W., Chen, F. K., & Liu, G.-S. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101110 · Cited by 51
Jones, A., Peers, K., Wierzbicki, A. S., Ramachandran, R., Mansfield, M., Dawson, C., Ochoa-Ferraro, A., Soran, H., Jenkinson, F., McDowell, I., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.05.008 · Cited by 39
Self-citationVolanesorsen: A New Era in the Treatment of Severe Hypertriglyceridemia
Kolovou, G., Kolovou, V., & Katsiki, N. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040982 · Cited by 33
Metadata
- Authors
- Esan, O., & Wierzbicki, A. S.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2020-07
- Volume
- Volume 14
- Pages
- 2623-2636
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W3038301709
- Cited by
- 80
- References
- 31
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.